Anti-PD-1 Polyclonal Antibody is a Rabbit antibody targeting PD-1. Anti-PD-1 Polyclonal Antibody can be used in FCM.

IgG

Human,Mouse,Rat

Blank control (blue line): Mouse spleen cells (blue).
Primary Antibody (green line): Rabbit Anti-PD-1/PE-CY7 Conjugated antibody (TMAB-01347-PE-CY7)
Dilution: 1 μg/10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG-PE-CY7. Protocol
The cells were fixed with 70% ice-cold methanol overnight at 4°C. The cells were then incubated in 1 X PBS/2% BSA/10% goat serum to block non-specific protein-protein interactions followed by the antibody for 15 min at room temperature. Cells stained with Primary Antibody for 30 min at room temperature.

FCM: 1μg /test

Polyclonal

KLH conjugated synthetic peptide: human PD-1

Human

PDCD1

Programmed cell death protein 1

CD,Regulatory T Cells,Death Receptors,CD markers,Apoptosis,Apoptosis

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed:21276005).Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed:21276005).Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity).Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity).The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28951311).The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed:28951311).The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed:22658127, PubMed:25034862, PubMed:25399552).